Champions Oncology Secures Radioactive Materials License for Radiotherapeutic Research

Champions Oncology, a leader in translational oncology research, has acquired a license to employ radioactive materials in its preclinical studies. This new capability enhances the company's potential to develop and evaluate targeted radiotherapeutics internally. The license enables the organization to conduct radionuclide-based therapeutic testing using its extensive patient-derived xenograft (PDX) models.

CEO Ronnie Morris emphasized the significance of this milestone, noting how the integration with their PDX platform supports the development of next-generation radiotherapeutics with high translational precision. This program is set to assist drug developers in creating various radiotherapeutic modalities.